Media ReleasesAuscann Group Holdings

View All Auscann Group Holdings News

AusCann, Quarterly Activities Report and Appendix 4C Quarter ended December 2018

AusCann advances the development of cannabinoid hard shell capsules


• Agreement with PCI Pharma to manufacture AusCann’s cannabinoid hard shell capsules

• DayaCann and Khiron Life Sciences to commence first cultivation activities under the MoU signed at the start of the Quarter

• Expanded medical educational program to drive engagement with medical practitioners in Australia

• CEO transition to support AusCann’s next phase of growth as a pharmaceutical company continued to progress and is now at an advanced stage

• AusCann on track for the production of cannabinoid medicines for use in clinical trials during this calendar year

31 January 2019 – Leading medical cannabis company AusCann Group Holdings Limited (ASX:AC8) (‘AusCann’ or ‘the Company’) is pleased to provide an overview of its activities for the three months ended 31 December 2018.

For further information please download PDF attached:
Download this document